EICHORCondition: Asthma · Sponsor: AstraZeneca
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
An event-driven, Phase III study to evaluate the efficacy and safety of BDA MDI compared with AS MDI in reducing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Baotou, China | Recruiting |
| Research Site | Baotou, China | Recruiting |
| Research Site | Beijing, China | Active Not Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Changchun, China | Recruiting |
| Research Site | Changchun, China | Recruiting |
| Research Site | Changsha, China | Recruiting |
| Research Site | Changsha, China | Recruiting |
| Research Site | Chengdu, China | Recruiting |
| Research Site | Chengdu, China | Recruiting |
+ 90 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06471257